Quantitative studies reporting HRQoL in patients with NASH
| |
Alt et al., 2016 [11]
|
Evaluate HRQoL in patients with CLD and in CLD patients divided by etiology, including NASH
|
Retrospective, cross-sectional, single-center study
|
Germany
|
CLDQ (German version)
|
IBM SPSS Statistic V.21.0 (IBM Corp., Armonk, NY)
|
Chawla et al., 2016 [12]
|
Assess HRQoL in patients with NASH and compare NASH vs normative US dataa
|
Prospective, cross-sectional, single clinic study
|
USA
|
SF-36, CLDQ
|
SAS V.8.2 (SAS Institute Inc., Cary, NC, USA)
|
David et al., 2009 [8]
|
Compare HRQoL in patients with NAFLD (with and without NASH) vs normative US population
|
Retrospective, cross-sectional, eight-center study (database and RCT data)
|
USA
|
SF-36
|
NR
|
Sayiner et al., 2016 [13]
|
Compare HRQoL in patients with cirrhotic NAFLD vs those with noncirrhotic NAFLD and also vs the general population
|
Prospective, cross-sectional, single clinic study
|
USA
|
SF-36 (and SF-6D health utility scores derived)
|
SAS (SAS Institute Inc., Cary, NC, USA)
|
Tapper and Lai, 2016 [14]
|
Assess HRQoL changes from baseline to 6 months in NAFLD and NASH patients with and without significant weight loss
|
Prospective, longitudinal (6-month) registry study
|
USA
|
CLDQ
|
JMP Pro statistical discovery (V.11; SAS Institute Inc., Cary, NC, USA)
|
Interventional trials reporting HRQoL impact of pharmacological therapies for NASHb
|
Chande et al., 2006 [15]
|
Determine the effects of an herbal medicine (YHK) versus placebo for 8 weeks on HRQoL (secondary outcome) in patients with NASH and persistently elevated transaminases
|
Prospective, longitudinal (8-week), randomized, double-blind, placebo-controlled, single-center, pilot study
|
Japan
|
SF-36
|
NR
|
Sanyal et al., 2010 [16]
|
Assess the change in HRQoL (secondary outcome) from baseline to the end of 96 weeks’ treatment with pioglitazone, vitamin E, or placebo in patients with NASH (without DM)
|
Prospective, longitudinal (96-week), randomized, double-blind, placebo-controlled, multicenter, phase 3 clinical trial
|
USA
|
SF-36
|
NR
|
Qualitative research in patients with NASH
| |
Palsgrove et al., 2016 [17]
|
Undertake qualitative research to inform the development of a conceptual model as part of the process of developing a NASH-specific PRO
|
Qualitative study (focus groups and individual interviews)
|
North America, Europe, South America, Australasia
|
Qualitative methods
|
MAXQDA Plus (VERBI GmbH, Berlin, Germany)
|